CD274 and triple-negative breast carcinoma: FPPa-Omomyc showed in vivo efficacy in a subcutaneous patient-derived mouse model of triple negative breast cancer (TNBC) when administered locally, decreasing proliferation, causing apoptosis, downregulating PD-L1, and extending mouse survival [85].